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Available online 25 November 2013Biopharmaceuticals administered to the human body have the potential to trigger the production of
anti-drug (also called anti-therapeutic) antibodies (ADA) that can neutralize the therapeutic
activity. For antibody therapeutics, cell-based neutralizing ADA assays are frequently used to
evaluate ADA in clinical studies. We developed a method to detect neutralizing antibodies against
MEDI-575, a fully human IgG2κ antagonistic antibody against PDGFR-α. We evaluated three assay
formats, two of which measured late responses, cell proliferation and apoptosis, whereas the third
assay detected an early signaling event, phosphorylation of PDGFR-α. Measuring phosphorylation
provided a superior assay window and therefore was developed as a neutralizing ADA (NAb) assay.
Matrix interference, however, was significant, and could be identified to be caused by PDGF-AA and
PDGF-AB, apparently the twomost abundant ligands of PDGFR-α present in human serum samples.
A simple pre-treatment step, addition of an inhibitory antibody to PDGF-A, a subunit present in
PDGF-AA and PDGF-AB, was found to eliminate matrix interference, increasing assay reliability and
sensitivity. We integrated the pre-treatment step into assay development and qualified a robust
NAb assay.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.Keywords:
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MEDI-5751. Introduction
Biopharmaceuticals have the potential of inducing the
generation of anti-drug antibodies (ADA) that could cause
undesired effects ranging from loss of drug exposure to
serious adverse events (Food and Drug Administration,
2013; Vugmeyster et al., 2012; Wadhwa et al., 2003).
Testing for ADA is a regulatory requirement when conducting
clinical studies and samples are commonly tested in a tiered
approach to evaluate and confirm ADA. Only samples that are
confirmed positive for ADA are subjected to testing by more
laborious and time-consuming neutralizing ADA (NAb) assays.M. Schwickart).
r B.V. Open access under CC BYNAb assays can be categorized by their format: ligand-binding
assays that measure neutralization of binding and cell-based
assays that measure the neutralization of a biological effect of
the drug. Cell-based assays, in contrast to ligand-binding
assays, are considered to provide a readout that is most
representative of the biological effect elicited by neutralizing
antibodies (Food and Drug Administration, 2009). However,
there are technical challenges to cell-based NAb assays. The
sensitivity is often inferior and results tend to bemore variable.
NAb assays are often influenced by sample components other
than neutralizing ADA, and if not addressed during assay
development, these components can result in false-positive
or false-negative results during clinical sample testing. This
so-called sample or matrix interference is caused by often
unknown factors that either generate nonspecific signals or
inhibit the specific signal. Matrix interference depends much
on assay design. NAb assays can detect either early or late
biological responses caused by the drug. Early responses are
signaling pathway activation events that occur soon after-NC-SA license.
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more downstream, such as cell proliferation, cell death, cell
differentiation and secretion of cellular products (Gupta et al.,
2007). Late responses tend to be the consequence of complex
cellular responses potentially influenced by pathways unrelat-
ed to the drug and therefore more amenable to matrix
interference.
Matrix interference in cell-based NAb assays and also
cell-free NAb assays can be eliminated by purification of total
antibodies from the sample (McCutcheon et al., 2010; White
et al., 2008). Such purification steps, however, have the
potential to influence the concentration or activity of the purified
antibodies, leading to an underestimation of NAb in clinical
samples. Therefore, the matrix interference and strategies to
eliminate such interferences are routinely evaluated during
method development. Relevant assay development consider-
ations are described in detail in the literature (Gupta et al.,
2007).
This study describes the development of a NAb assay to
detect neutralizing ADA directed against MEDI-575, a mono-
clonal fully human antibody to PDGFR-α.
2. Material and methods
2.1. Reagents
Fully human monoclonal antibody IgG2κ (MEDI-575) was
produced and purified byMedImmune. Rabbit antisera against
MEDI-575 were produced at Eurogentec SA (Liege, Belgium). A
polyclonal antibodydirected againstMEDI-575 (positive control
pAb) was purified form terminal bleed antisera by precipitation
with ammonium sulfate, followed by purification onMEDI-575
affinity columns, and depletion on isotype control affinity
columns. Normal human serum and cancer serum samples
were purchased from Bioreclamation (Westbury, NY) and
informed consent was obtained from all donors. Human
PDGF-AA affinity purified polyclonal antibody (Goat IgG),
recombinant human PDGF-AB, PDGF-BB, PDGF-CC, PDGF-DD,
and PDGFR-α were purchased from R&D Systems (Minne-
apolis, MN). Recombinant human PDGF-AA was purchased
from Austral Biologicals (San Ramon, CA). 4G10® Platinum
(anti-phosphotyrosine) was purchased from Millipore
(Temecula, CA). Anti-PDGFR-α (D1E1E) XP™ rabbit mAb was
purchased from Cell Signaling Technology (Danvers, MA).
Sulfo-Tag labeled anti-rabbit antibody, Tris lysis buffer and
4× Read Buffer T were purchased from Meso Scale Discovery
(Gaithersburg, MD). Phosphatase inhibitor cocktail 2 and
phosphatase inhibitor cocktail 3 were purchased from
Sigma-Aldrich (Saint Louis, MO). Complete protease inhib-
itor cocktail tablet was purchased from Roche Diagnostics
(Indianapolis, IN). Caspase-Glo® 3/7 assay and CellTiter-Glo
luminescent cell viability assay were purchased from Promega
(Madison,WI). I-Block was purchased from Applied Biosystems
(Carlsbad, CA), RPMI-1640 (+25 mM HEPES + L-glutamine),
and characterized fetal bovine serum (FBS), trypsin 0.25% (1×)
solution and penicillin–streptomycin solution (10,000 IU/mL
penicillin, 10,000 μg/mL streptomycin) were purchased from
Hyclone Laboratories, Inc. (Logan, UT). 1× phosphate buffered
saline (PBS without Ca++/Mg++ or phenol red) and water for
cell culture applications were purchased from Lonza Group,
Ltd. (Allendale, NJ).2.2. Growth and maintenance of cells
The human squamous adenocarcinoma cell line, NCI-H1703,
was obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and maintained in cell growth media
(RPMI-1640 + 25 mMHEPES + L-glutaminemediumsupple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin–
streptomycin solution). Cells were cultured at 37 °C in a
humidified 5% CO2 incubator in a 75 cm2 or 150 cm2 cell
culture flask (BD Biosciences, San Jose, CA). For routine cell
culture, cells were plated at 3 × 106 cells in a T75 cell culture
flask and passaged every 2–3 days.
2.3. Control samples and sample preparation for PDGFR-α
phosphorylation assay
If not otherwise specified, all controls and samples were
diluted to 50% with assay diluent (RPMI-1640 + 25 mM
HEPES + L-glutamine medium supplemented with 0.4% FBS
and 1% penicillin–streptomycin solution). Assay performance
was monitored by two positive controls, a negative control,
and an assay control. 2500 ng/mL (high positive control)
and 1500 ng/mL (low positive control) of neutralizing pAb
were prepared in assay matrix (50% normal human serum,
300 ng/mL MEDI-575 and 5 μg/mL anti human PDGF-AA).
Negative control consisted of assay matrix. The assay control
contained assay matrix without MEDI-575. To determine the
LLOD, neutralizing pAb was titrated to a final concentration
of 16,000, 8000, 4000, 2000, 1000, 500, 250, and 125 ng/mL
in assay matrix. Controls and test samples were incubated at
room temperature for 80 min with gentle agitation and then
incubated on ice for approximately 30 min before addition to
NCI-H1703 cells.
2.4. General procedure PDGFR-α phosphorylation assay
A cell suspension of 150,000 cells/mL in growth media
was plated in each well of a clear 96-well flat bottom tissue
culture plate (Corning, NY) at 100 μL/well. After approxi-
mately 24 h, cells were serum-starved by replacing the
cell growth media with 100 μL/well of assay diluent. After
approximately 12–20 h of incubation, the plate containing
cells was incubated with samples and controls. Fifty micro-
liters of the test samples and controls were transferred to the
cells, and incubated at 2–8 °C for approximately 2 h. The
supernatant was discarded and phosphorylation of PDGFR-α
was stimulatedwith 150 ng/mL recombinant human PDGF-AA
for 20 min at 37 °C in a humidified 5% CO2 incubator. The cells
were lysed with lysis buffer cocktail (Tris lysis buffer +
complete protease inhibitor cocktail tablet + phosphatase
inhibitor cocktail 2 and 3).
Phosphorylation of PDGFR-α in the cell lysate was mea-
sured with a plate-based immunoassay. Standard 96-well MSD
plates were coated overnight at 2–8 °C with 35 μL of 4 μg/mL
4G10® Platinum (anti-phosphotyrosine) in 1× PBS. Coated
plates were washed and blocked with 150 μL I-Block Buffer
(0.2% I-Block, 0.5% Tween 20 in 1× PBS) at room temperature
for 1 h. The plate was washed and cell lysate was added and
incubated for 1 h at room temperature. Afterwashing the plate
with 1× wash buffer (PBS, 0.0% Tween 20), 35 μL of 0.5 μg/mL
monoclonal anti PDGFR-α rabbit antibody prepared in I-Block
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temperature for 1 h. Wells were washed and 35 μL of 0.5 μg/mL
Sulfo-Tag labeled anti-rabbit antibody prepared in I-Block
buffer was added to the plate for 1 h at room temperature.
After another wash step, 1× Read Buffer T was added and the
electrochemiluminescence (ECL) was measured with a MSD
Sector Imager 2400 or 6000.2.5. Assay precision
The assay precision was evaluated based on the intra-assay
precision of the assay response (assay signal of sample divided
by assay signal of negative control on same plate) of the high
positive control, low positive control, negative control and
assay control using passage 4 through passage 19. Intra-assay
precision was evaluated using data from four replicates on one
plate. The inter-assay precision was evaluated between the
mean assay responses of the plate controls executed on
different days.2.6. Matrix and drug interference in serum samples
To evaluatematrix interference, eight patient serumsamples
were spiked with 50 ng/mL PDGF-AA and tested with and
without pre-treatment with anti-PDGF-A. Five patient serum
samples, one normal serum sample, and pooled normal human
serum with addition of either 200 ng/mL PDGF-AA, 200 ng/mL
PDGF-AB, 20 ng/mL PDGF-BB or 20 ng/mL sPDGFR-α were
tested in the presence of 2500 ng/mL or 1500 ng/mL neutral-
izing pAb. Drug interference was evaluated with a titration of
neutralizing pAb ranging from 500 ng/mL to 16,000 ng/mL in
the presence of 10,000, 4000, 1600, 640, 256, and 102.4 ng/mL
of MEDI-575 in assay matrix.2.7. Data analysis
To determine EC50 and the upper and lower asymptote,
data was fitted to a four-parameter model using Sigma
Plot 11 (Systat Software). JMP 8.01.1 (SAS Institute) was used
to determine cutpoints at a 1% false positive rate. First,
normality was evaluated using the Shapiro–Wilk test. If data
were normally distributed, outliers were identified by the
mean and standard deviation and removed from the dataset.
The cutpoint was calculatedwith: cutpoint = mean + 2.326 ×
SD. The LOD signal was calculated assuming a 1% false positive
and 5% false negative rate with: LOD signal = cutpoint +
1.645 × SD. The LOD was determined from data obtained in
three independent titrations of neutralizing pAb. The param-
eters defined in the four-parameter model were then used to
calculate the LOD from the LOD signal. In case the datawere not
normally distributed, a log transformation was performed and
normality was confirmed with the Shapiro–Wilk test. If data
were still not normally distributed, outliers were identified by
using the inter-quartile range and removed from the dataset.
Normality was then again confirmed with the Shapiro–Wilk
test. The Log transformed cutpoint was determined from the
log-transformed data as described above. The cutpoint was
calculated with anti-log transformation.2.8. Acceptance criteria of the NAb assay (phosphorylation assay)
Several criteria were defined to monitor the performance
of the NAb assay. The intra-assay %CV of four replicates of the
negative control and positive control had to be below 25%.
The positive control had to be above the cutpoint. The assay
window as judged by the fold difference between negative
control and control in the absence of MEDI-575 had to be
higher than 2.9.
2.9. Apoptosis assay
MEDI-575 was titrated in growth media (RPMI-1640 +
25 mM HEPES + L-glutamine medium supplemented with
10% fetal bovine serum (FBS) and 1% penicillin–streptomycin
solution) and thirty microliters of the titration was added
to each well of a 96-well white ViewPlate (PerkinElmer
Waltham, MA). 30 μL of NCI-H1703 cells in growth media at
0.5 × 106 cell/mL were added and agitated gently to mix.
The plates were incubated for approximately 24 h at 37 °C in
a humidified 5% CO2 incubator and equilibrated at room
temperature for 10–20 min. 50 μL of Caspase-Glo 3/7 substrate
was added to all wells, gently mixed, and incubated for 60 min
at room temperature. Luminescence was then measured using
a luminometer (Victor3 1420 Multilabel Counter, PerkinElmer,
Shelton, CT) at an integration time of 0.1 s per well.
2.10. Cell proliferation assay
MEDI-575 was titrated in NCI-H1703 cell suspension at a
final cell density of 1 × 105 cells/mL. Final concentration of
MEDI-575 was 100,000, 25,000, 6250, 1562.5, 390.6, 97.7,
24.4, 6.1, and 1.5 ng/mL in assay diluent (RPMI-1640 +
25 mM HEPES + -glutamine medium supplemented with
0.4% FBS and 1% penicillin–streptomycin solution) containing
30 ng/mL recombinant human PDGF-AA. After 5 min of gentle
agitation at room temperature, the plates were incubated for
approximately 72 h at 37 °C in a humidified 5% CO2 incubator.
The plates were then equilibrated at room temperature for
approximately 30 min followed by addition of 100 μL/well of
CellTiter-Glo reagent. After mixing, the plates were incubated
at room temperature for 10 min. Plates weremeasured using a
luminometer (Victor3 1420 Multilabel Counter, PerkinElmer,
Shelton, CT) with an integration time of 0.1 s per well.
2.11. Relative quantitation of PDGF (PDGF-AA, PDGF-AB, PDGF-
BB, PDGF-CC)
PDGF-AA in human serum samples was quantified by the
Milliplex™ MAP Human Cytokine/Chemokine Kit (Millipore
Corporation, Billerica, MA). Reference standard, quality control
samples, and human serum samples diluted 1/200 in kit
diluent were prepared and evaluated per the manufacturer's
instructions. PDGF-AA reference standard curves (5-PL) were
plotted in SoftMax Pro GxP v5.2 software (Molecular Devices,
Sunnyvale, CA). The assay range was 0.032 to 2 ng/mL in kit
diluent (or 0.640 to 400 ng/mL back calculated to 100% serum).
PDGF-AB and PDGF-BB in human serum were determined by
commercially available DuoSet ELISA Development Systems
assays (R&DSystems,Minneapolis,MN). Human serumsamples
were diluted 1/40 and 1/20 in kit diluent for PDGF-AB and
MEDI-575 (ng/ml)
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manufacturer's instructions. PDGF-AB and PDGF-BB assays
ranges were 0.0156 to 1 ng/mL and 0.0156 to 2 ng/mL,
respectively, in kit diluent (or 0.624 to 40 ng/mL and 0.312 to
40 ng/mL, respectively, back calculated to 100% serum).
PDGF-CCwas determined using a human PDGF-CCQuantikine®
ELISA kit (R&D Systems). Serum sampleswere diluted 1/2 in the
respective kit diluent and evaluated per Quantikine® ELISA
instructions. The assay range for PDGF-CC determinations was
0.125 to 4 ng/mL in kit diluent (or 0.250 to 8 ng/mL back
calculated to 100% serum). The PDGF-AA, PDGF-AB, and
PDGF-BB assays were specific to their respective analyte with
one exception. The PDGF-BB assay did detect PDGF-AB at 10%
of its nominal concentration.PD
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Fig. 1. Dose response curves of three assays measuring cellular responses to
MEDI-575. H1703 cellswere incubatedwith a titration ofMEDI-575. After 72 h,
cell viability was assessed using CellTiter-Glo (A). Apoptosis was quantified
after 24 h of incubation using Caspase-Glo 3/7 activity as readout (B). To
measure PDGFR-α phosphorylation, cells were incubated for 2 h, inducedwith
PDGF-AA, lysed and subjected to a plate-based assay to detect phosphorylated
PDGFR-α (C). Data are expressed as a percentage of luminescent signal in the
absence of MEDI-575. Data points (mean of triplicate measurements) and a
four-parameter fit are shown. Error bars show the standard deviation of
triplicate measurements. The lower asymptote (min), the upper asymptote
(max) and the EC50 is shown for each assay (A, B and C).3. Results
3.1. Initial selection of assay format
NAb assays are often based on potency assays and
are then optimized to be suitable for clinical testing of
neutralizing ADA (NAb). Here, we explored the suitability of
research-grade activity assays and potency assays as a
starting point for NAb assay development. MEDI-575
inhibits PDGFR-α which causes inhibition of cell prolifera-
tion and increases apoptosis in responsive cell lines.
NCI-H1703, a non-small cell lung cancer cell line with high
expression of PDGF-Rα, (McDermott et al., 2009), was incubated
with increasing concentrations of MEDI-575 and cell viability
was measured after 72 h (Fig. 1A). Apoptosis was determined
24 h after incubation with MEDI-575 (Fig. 1B). To measure
phosphorylation of PDGFR-α, cells were incubated with
MEDI-575 for 2 h in the cold to allow binding but not signaling,
and then subsequently induced with PDGF-AA for 20 min
before lysis. Phosphorylation of PDGF-Rα in the cell lysate was
detected by a plate-based immunoassay (Fig. 1C). Data were
acquired in triplicate and EC50, lower asymptote, and upper
asymptote, were determined by curve fitting. MEDI-575
inhibited the signal reflecting cell viability to 46.2% of control,
increased the signal indicative of activity of Casp3/7 to 143.0%
of control, and inhibited PDGFR-α phosphorylation to 7.1% of
control. The EC50 of MEDI-575 for the proliferation assay, the
apoptosis assay and the phosphorylation assay was 215.3 ng/
mL, 602.6 ng/mL, and 326.7 ng/mL, respectively. The largest
assay window was observed in the phosphorylation assay
(~14-fold) whereas both proliferation assay and apoptosis
assay only had a 1.4 to 2.3-fold assay window. NAb assays
depend on addition of drug at partially inhibiting concentra-
tions to show the effect of neutralizing ADA (Food and Drug
Administration, 2009). Consequently, the effective assay
window for the NAb assay is expected to be a fraction of the
initial window of the drug dose response curve. Measuring
PDGFR-α phosphorylation provided the largest assay window
and assay development was continued only with this format.
The EC50 of MEDI-575 in different assays was considered
comparable, however the apoptosis tended to have the highest
EC50. Additionally, a short incubation time of sample with cells
for the phosphorylation assay is expected to generally lead to
less matrix interference and has the benefit of a faster sample
turnaround.3.2. Serum interference
Serum components are often a source of interference in
NAb assays and dilution of patient sample (serum or plasma)
is necessary to reduce effects unrelated to the neutralizing
ADA. To investigate the influence of sample dilution on assay
performance, independent of disease-related interference,
we measured PDGFR-α phosphorylation in the presence of
increasing concentrations of MEDI-575 in three dilutions of
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12.5%). The data was fitted to a four-parameter model
(Fig. 2). The assay windows as well as the EC50 were
comparable in all three investigated dilutions of NHS and
we continued assay development with a dilution of 50%
serum. This dilution leaves sufficient volume for addition of
necessary components during assay development and also
aims for higher assay sensitivity by using a low sample
dilution. It should be noted here that an accurate determina-
tion of optimal dilution, evaluated by sensitivity and assay
window, should be performed by titrating the neutralizing
control antibody in several individual serum samples. Our
polyclonal neutralizing control antibody (pAb) at the time of
assay development was raised in rabbit and therefore its
quantity was limited. We therefore minimized its use and
investigated optimal sample dilution by titrating MEDI-575.3.3. Matrix interference
We tested a total of 50 serum samples from cancer
patients with the phosphorylation assay in the presence of a
partially inhibiting concentration of 300 ng/mL MEDI-575
(Fig. 3A), a concentration that corresponded approximately
to the EC50 (Fig. 1C). An assay response was defined as the
ratio between the ECL signal of the sample and the ECL signal
of the negative control (50% pooled normal human serum
with 300 ng/mL MEDI-575) on the same assay plate. The
assay response in naive samples was generally high with a
mean of 1.852 and also variable. Data of all 50 samples was
normally distributed and, assuming a 1% false positive rate,
resulted in a preliminary cut point of 2.849. The LOD signal of
3.652 was determined applying a 1% of false-positive rate and
a 5% false-negative rate. The assay window in a titration of
neutralizing pAb (Fig. 3B) was approximately between 4 and
5; the preliminary cutpoint of 2.849 and LOD signal of 3.652
were high relative to the maximal assay signal. A high
cutpoint suggests high matrix interference, and the observedMEDI-575 (ng/ml)
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Fig. 2. Influence of serum concentration in PDGFR-α phosphorylation assay.
H1703 cells were incubated with diluted pooled normal human serum
containing a titration of MEDI-575, induced with PDGF-AA, and lysed, and
phosphorylation of PDGFR-α was determined by a plate-based assay. Data
points and a four-parameter fit are shown in the presence of 50% NHS (open
circles, solid line), 25% NHS (open squares, dotted line), and 12.5% NHS
(open triangles, dashed line).variability in assay signal in different samples suggests that
concentration of interfering factor(s) varies between samples.
We hypothesized that the high assay signal in many
individual patient sera was due to the presence of PDGFR-α
ligands (Fredriksson et al., 2004) which can lead to
phosphorylation of the receptor and interfere with the NAb
assay. Several members of the PDGF family, PDGF-AA, PDGF-AB,
PDGF-BB, and PDGF-CC, are reported to bind and activate
PDGFR-α (Fredriksson et al., 2004). Additionally, a soluble form
of PDGFR-α (sPDGFR-α), reportedly present at low levels in
human serum, (Tiesman and Hart, 1993) could potentially
interfere by binding and blocking MEDI-575 present in the
assay. PDGF-AA, PDGF-AB, and PDGF-BB are present in serum
of cancer patients (Pasanisi et al., 2008; Rahbari et al., 2011;
Rykala et al., 2011). PDGF-CC was previously detected in the
serum of stroke patients (Rodriguez-Gonzalez et al., 2013).
PDGF is generally elevated in samples from cancer patients (Li
and Eriksson, 2003). Additionally PDGF is released during
serum preparation from platelets (Huang et al., 1983),
further increasing the potential interference in serum
samples.
We investigated the concentration of PDGF-family mem-
bers in 50 serum samples (Fig. 4A), which were identical to
the samples subjected to the NAb assay. The concentration of
PDGF-AA and PDGF-AB was highest with a mean concentra-
tion of 12.3 (45.9–2.1) ng/mL and 12.2 (45.6–1.9) ng/mL,
respectively. The mean concentration of PDGF-BB was 3.3
(12.0–0.7) ng/mL and PDGF-CC had a mean concentration of
1.2 (4.6–0.3) ng/mL (Fig. 4A). We also attempted to measure
a soluble form of the PDGFR-α, but were unable to detect it in
any of 50 serum samples. Both PDGF-AA and PDGF-AB
correlated significantly (p b 0.0001) with the assay response
of these naive samples in the NAb assay (Pearson's r for
PDGF-AA = 0.755, the 95% confidence interval ranged from
0.603 to 0.854, Fig. 4B; Pearson's r for PDGF-AB = 0.829; the
95% confidence interval ranged from 0.716 to 0.900, Fig. 4C).
Due to the strong correlation between assay response in NAb
assay and the serum concentration of PDGF-AA and PDGF-AB,
we hypothesized that sample interference is caused by PDGF
in the samples.
To test whether PDGF and sPDGFR-α can interfere with
the assay, we performed a titration in pooled normal human
serum (Fig. 5A). Since PDGF-AA, PDGF-AB and PDGF-BB bind
and activate PDGFR-α (Li and Eriksson, 2003), we were not
surprised to find interference starting at physiologically
relevant concentrations. PDGF-AB appeared to be most potent,
consistent with a reported 10-fold higher affinity to PDGFR-α
expressing cells when compared to PDGF-AA (Seifert et al.,
1993). PDGF-AA was less potent than PDGF-AB and PDGF-BB.
Surprisingly, PDGF-CC did not interfere with the assay at the
tested concentrations. PDGF-CC is reported to bind and activate
PDGFR-α (Gilbertson et al., 2001), and also lead to proliferation
in NCI-H1703 cells (McDermott et al., 2009). We can only
speculate that the PDGF-CC used in our study, might be only
partially active or that PDGF-CC in the NCI-H1703 cell line does
not lead to phosphorylation of PDGFR-α in the observed time
frame. It is also conceivable that the activity of the recombinant
material differs from endogenous as suggested previously
(Seifert et al., 1993), and consequently, results with recombi-
nant material might only be able to indicate rather than
quantitatively predict assay interference from endogenous
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Fig. 3. Matrix interference and dose response curve of neutralizing pAb. H1703 cells were incubated with 10 serum samples each from individuals with ovarian
cancer, non-small cell lung cancer (NSCLC), colon cancer, breast cancer, and prostate cancer with and without pre-treatment with anti-PDGF-A antibody in the
presence of 300 ng/mL MEDI-575. After washing, cells were induced with PDGF-AA, and lysed, and phosphorylation of PDGFR-α was determined (A). The assay
response is the assay signal divided by the negative control on each assay plate. The preliminary cutpoint is shown as a dashed line for samples that were not
subjected to pre-treatment (open circles) and as a solid line for samples subjected to pre-treatment (closed circles). A titration of neutralizing pAb was performed
(B). Symbols display the mean whereas error bars represent the standard deviation of results obtained on three different days. Cutpoint and LOD with and
without pre-treatment are included and labeled in (B).
57M. Schwickart et al. / Journal of Immunological Methods 403 (2014) 52–61PDGF. Lastly, it is possible that PDGF-CC does not compete with
MEDI-575 for binding to the receptor and therefore no
interference is observed. PDGF-DD is reported to not bind to
PDGFR-α and was used as a control. Furthermore, the soluble
receptor (Tiesman and Hart, 1993) caused an increased assay
response (Fig. 5A), most likely by binding MEDI-575 in the
sample, leading to a depletion of active MEDI-575, which left
more cellular receptors available for binding and phosphory-
lation by PDGF-AA. We then used an antibody to the PDGF-A
subunit in order to block PDGF-AA and PDGF-AB in serum.
The effect of PDGF-AA and PDGF-AB was completely inhibited
by pre-treatment with anti-PDGF-A (Fig. 5B). The effect of
PDGF-BB was partially inhibited likely due to an existing
cross-reactivity of the antibody to PDGF-B (R&D Systems, Data
sheet for AF-221-NA). The effect of the soluble receptor
PDGFR-α, as expected, could not be inhibited with anti-
PDGF-A (Fig. 5B). This pre-treatment would eliminate inter-
ference caused by the majority and most abundant potential
interfering factors. We continued to test whether this was
sufficient to block interference in commercially available
serum samples from cancer patients.
We tested the identical set of 50 samples in the presence
of pre-treatment (anti-PDGF-A, Fig. 3A) and found that the
observed interference was inhibited, suggesting that
PDGF-AA, PDGF-AB and/or PDGF-BB were causative of the
interference. The mean assay response of 1.174 withpre-treatment (compared to 1.852 without pre-treatment)
was comparable to the assay response in pooled normal human
serum. The data in the presence of anti-PDGF-A was normally
distributed and the preliminary cutpoint (1% false positive
rate) was 1.596; the LOD signal (1% false positive rate and 5%
false-negative rate) was 1.895 which was significantly lower
compared to the cutpoint and LOD signal in samples without
pre-treatment, 2.849 and 3.652 respectively (Fig. 3B).
Assay development is typically carried out with commer-
cially available patient samples to mimic patient samples in
clinical studies. However, these samples serve only an approx-
imation of the samples used during human studies. The
prospective drug and co-medication might cause unique
changes in the study subject that are not present in patient
samples used during assay development and validation. During
assay developmentwe became aware thatMEDI-575 causes an
increase in PDGF-AA during a human study (data not shown).
To investigate whether the increase could affect the assay,
50 ng/mL PDGF-AA, a concentration slightly above the highest
observed concentration in the clinical study (unpublished
data), was spiked into eight individual patient sera (Fig. 5C),
and the spike further increased the assay signal over the
already existing interference in all eight samples. The median
assay response was 1.55 in naive samples, and was reduced to
1.01 after treatment with anti-PDGF-A. Samples spiked with
50 ng/mL PDGF-AA showed a median assay response of 2.15
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Fig. 5. Interference through PDGF and soluble receptor PDGFR-α PDGF and
soluble PDGFR-α were titrated into 50% NHS containing 300 ng/mL
MEDI-575 with (B) or without (A) anti-PDGF-A. The mixture was then
incubatedwith H1703 cells and cells were then inducedwith PDGF-AA, and
lysed, and PDGFR-α phosphorylation was measured (A, B). The assay
response is equal to ratio between the assay signal and the negative control
on each assay plate. Titrations in (A) and (B) are shown for PDGF-AA (open
squares), PDGF-AB (closed squares), PDGF-BB (open circles), PDGF-CC
(closed circles), PDGF-DD (open triangles), and soluble PDGFR-α (closed
triangles). Eight cancer patient sera were spiked with 50 ng/mL PDGF-AA
and then measured in the phosphorylation Nab assay with and without
anti-PDGF-A pre-treatment (C).
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interference and the interference originating from the PDGF-AA
spike could be inhibited by pre-treatment with anti-PDGF-A.
We used a twenty-fold molar excess of anti-PDGF-A antibody
over the spiked concentration of PDGF-AA.
3.4. Assay qualiﬁcation
3.4.1. Cutpoint
During qualification of the assay, cutpoint was determined
with 36 patient samples that were different from samples used
during development. The samples were tested in duplicate and
on two different days. The mean of duplicate testing, or 72 data
points, were used to determine the cut point (Klakamp et al.,
2007). The Shapiro–Wilk test was used to determine normality
of the data. In contrast to patient sample data obtained duringdevelopment, the datawas found to be not normally distributed.
After log transformation, the data became normally distributed.
Eight outliers were removed and the standard deviation and
mean of the log-transformed data were used to determine the
cutpoint at an assay response of 1.588 assuming a 1%
false-positive rate (log transformed cutpoint: 0.2001). The
LOD signal was determined assuming a 1% false-positive
and a 5% false-negative rate at 2.322, which translated to a
LOD of 2440.6 ng/mL neutralizing pAb back calculated to
Table 2
Matrix interference in normal and disease serum samples and NHS spiked
with potentially interfering proteins.
Sample Assay response
High PC: 2500
ng/mL pAb
Low PC: 1500
ng/mL pAb
No
pAb
NSCLC 3.65 3.11 1.56
Glioblastoma 3.48 3.32 1.28
Prostate cancer 4.11 3.57 1.51
Colon cancer 4.16 3.27 1.24
Endometrial cancer 2.48 2.36 0.92
Normal 3.23 2.91 0.96
NHS + 200 ng/mL
PDGF-AA
4.41 3.17 0.96
NHS + 200 ng/mL
PDGF-AB
4.27 2.58 0.90
NHS + 20 ng/mL
PDGF-BB
4.40 3.39 0.83
NHS + 20 ng/mL
sPDGFR-α
4.00 2.82 0.93
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Material and methods for details.
3.4.2. Precision and cell passage
Precision was determined in nine assays on 9 different
days. Intra- and inter-assay precision was determined using
the high positive control (2500 ng/mL neutralizing pAb), low
positive control (1500 ng/mL neutralizing pAb), and assay
control (no MEDI-575). The assay was run on nine different
days using cells passaged between 4 and 19 times (Table 1).
In all three controls, the intra-assay precision ranged between
0.3%CV and 18.3%CV; the inter-assay precision ranged between
14.6%CV and 23.5%CV. The low positive control and high
positive control had assay responses between 1.7 and 5.1 and
were above cutpoint in all nine assay runs.
3.4.3. Matrix interference
Sample interference might mask neutralizing ADA and
lead to false negative results. We spiked neutralizing pAb into
5 individual patient sera and one normal serum. Both spikes
equivalent to the low positive control (1500 ng/mL) and high
positive control (2500 ng/mL) were detected as positive
(above cutpoint). Both control concentrations were also
detected above cutpoint when spiked to normal serum
containing 200 ng/mL additional PDGF-AA, PDGF-AB, 20 ng/mL
PDGF-BB or soluble PDGFR-α. The same samples without
neutralizing pAb were below cutpoint in all tested samples
(Table 2). Concentrations of PDGF ligands and soluble PDGFR-α
were chosen based on our results (Fig. 4A) and observed
accumulation of PDGF-AA during a clinical study (unpublished
data).
3.4.4. Drug interference
NAb assays typically contain partially inhibiting concen-
trations of drug. Additional drug present in the clinical
sample is expected to inhibit the ability of the assay to detect
neutralizing ADA and can lead to false negatives during
sample testing. We determined the ability of the assay to
detect neutralizing pAb at different MEDI-575 concentrations
(Table 3). 16,000 ng/mL neutralizing pAb was detected as
positive in the presence of 1600 ng/mL MEDI-575. 8000 ng/mL,
4000 ng/mL, and 2000 ng/mL neutralizing pAb was detected as
positive in the presence of 640 ng/mL, 256 and 102.4 ng/mLTable 1
Precision.
High PC: 2500 ng/mL pAb
Assay response Intra-assay
precision (%CV)
Passage 4 5.1 18.3
Passage 5 4.2 1.8
Passage 9 3.6 6.8
Passage 10 3.3 10.9
Passage 11 4.2 4.0
Passage 12 4.3 4.8
Passage 15 4.9 2.9
Passage 16 3.5 4.4
Passage 19 4.7 10.5
Inter-assay-precision (%CV) 14.9
Mean of all intra-assay precision (%CV)MEDI-575, respectively. MEDI-575 in the sample would mask
neutralizing ADA and could lead to false-negatives.
3.4.5. Robustness
Robustness was evaluated by using 20% more cells
(18,000 cells/well) or 20% less cells (12,000 cells/well) in
the assay compared to 15,000 cells/well as specified in the
procedure. All controls passed acceptance criteria as specified
in Material and methods (data not shown).
4. Discussion
Neutralizing ADA assays are an integral part of clinical
immunogenicity testing. For both cell-based NAb assays and
ligand-binding NAb assays, specificity and sensitivity are
critical parameters. Cell-based NAb assays might be more
reflective of the true biological impact of the NAb, however,
ligand-binding assays tend to be more sensitive and less
variable. Low sensitivity represents a major downside, chal-
lenging sometimes the usefulness for the evaluation of NAb
incidence in clinical studies. Due to a more complex assay
system, the read-out in cell-based assay is influenced by many
more factors compared to ligand-binding assays and as a resultLow PC: 1500 ng/mL pAb AC: no MEDI-575
Assay response Intra-assay
precision (%CV)
Assay response Intra-assay
precision (%CV)
2.8 0.3 4.6 14.1
1.7 14.7 4.9 14.5
2.9 10.8 3.8 4.0
3.0 7.6 3.4 8.5
1.8 15.5 4.5 16.2
2.8 4.3 4.3 5.5
3.2 15.6 5.0 8.1
2.4 9.2 3.3 8.5
3.8 16.9 4.5 7.8
23.5 14.6
9.1
Table 3
Drug interference.
MEDI-575 (ng/mL)
pAb (ng/mL) 10000 4000 1600 640 256 102.4 0
16,000 0.47 0.56 4.82 4.18 4.50 4.03 3.78
8000 0.40 0.50 0.71 4.27 4.75 4.80 3.83
4000 0.41 0.47 0.59 1.17 4.64 4.75 3.95
2000 0.38 0.50 0.57 0.68 1.32 2.68 3.35
1000 0.33 0.43 0.55 0.59 0.70 1.17 1.61
Assay response in bold indicates a positive result for neutralizing activity.
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becomes a major part of assay development. Matrix interfer-
ence creates a sample-specific assay background, which is
often high when late responses like proliferation or cell
viability are monitored, due to the fact that such late readouts
are a reflection of a sum of factors present in the sample that
affects cell growth or survival. Controlling matrix interference
is crucial to develop a reliable assay to detect neutralizing ADA.
We evaluated two late responses, proliferation and apopto-
sis, and one early event, receptor phosphorylation, as readouts
for the cell-based NAb assay. The EC50, used as an approxima-
tion of sensitivity, in all three assayswas comparable. However,
the assay window in these three assays was dramatically
different between assays. The assay window of the phosphor-
ylation assay was highest with 14-fold, followed by prolifera-
tion (2.3-fold) and apoptosis (1.4-fold). The difference in assay
window might be a testament of how specific the observed
cellular event (readout) is to the activity of the drugMEDI-575.
Although we used a cell line that overexpresses PDGFR-α and
express very little related receptor PDGFR-β (Thomson et al.,
2008), proliferation as well as apoptosis are still influenced by
many other factors, and signaling from PDGFR-α only contrib-
utes to a fraction of these late responses. Itwould be interesting
to investigate whether it is possible to eliminate alternative
signaling pathways and make the cell line NCI-H1703 more
responsive to activation of a single receptor and render
proliferation/apoptosis a more suitable readout for NAb assay
development. Measuring receptor phosphorylation is not
influenced by signaling of other functionally related receptors
that might, due to the complexity of the sample matrix, lead to
variability in the readout of late responses.
Engineered cell lines might be another way to improve
specificity of cell based assays. However, engineering might
also alter the cell line so much that the system does not
fully reflect the inhibition of the drug mechanism of action
(MOA) by the neutralizing ADA in the patient. This might be
especially relevant when several receptors are part of the
MOA and overengineering can bias the readout to only one of
several affected pathways.
Incubation time might be another factor that limits matrix
interference. Our phosphorylation assay had a short sample
incubation time of 2 h compared with the sample incubation
time of 3 days during the proliferation assay and 24 h during
the apoptosis assay. The induction of phosphorylation by
PDGF-AA was performed after sample was incubated and
removed from the cells. The phosphorylation assay there-
fore also opened up the possibility of temporal and spatial
separation of the assay readout andmatrix interference, furtheravoidingmatrix interference. A short incubation time leads also
to a shorter assay, increasing sample throughput.
Although our assay designwas expected tominimize sample
interference, we still observed significant matrix interference in
naive patient serum samples. Due to the fact that PDGFR-α
phosphorylation is a direct result of receptor activation, a
hypothesis-driven approach could be implemented to identify
the interfering factor. In serum samples from 50 individuals,
levels of PDGF-AA and PDGF-ABwere high relative to the other
PDGFR-α activating ligands PDGF-BB and PDGF-CC. Both
PDGF-AA and PDGF-AB levels correlated significantly with the
interference observed in the NAb assay. Addition of recombi-
nant PDGF-AA, -AB, and -BB resulted in an increase in assay
response (Fig. 5A) which proved that these ligands are able to
cause interference. Consequently, we designed a targeted
approach to inhibit these factors in individual patient samples
with an antibody to the ligand subunit PDGF-A. The antibody
binds and inhibits PDGF-AA, PDGF-AB, and to a lesser degree
PDGF-BB, and eliminated the majority of matrix interference.
The identification and elimination of matrix interference are
often challenging, and, if the source of interference cannot be
identified, purification of total immunoglobulin from the matrix
might be the only venue to build a neutralizing antibody assay
(McCutcheon et al., 2010; White et al., 2008). Pre-treatment
steps based on removal of matrix components have to be
evaluated regarding the potential loss of isotypes of neutraliz-
ing ADA and therefore may be a valid option when the source
of matrix interference cannot be identified.
The final assay consists of a two-step procedure, where the
cell-based step is followed by detection of the phosphorylated
receptor in an immunoassay. We expected an increased
variability due to the two-step procedure, however, the
assay proved to be of sufficient precision during qualification
(Table 1) with a mean intra-assay precision of 9.1%CV and
a maximal inter-assay precision of 23.5%CV. As with many
cell-based NAb assays, the drug tolerance was poor. Only if
neutralizing pAb is present at approximately ten times higher
concentrations than MEDI-575 in the sample, the assay
detected the neutralizing antibody. Assuming that our neutral-
izing pAb reflects NAb present in patient samples, NAb present
at less than 10-fold molar excess over MEDI-575 would result
in a false negative result. Therefore, definitive negative results
can only be expected if samples are collected during the
wash-out period when the drug levels are expected to be very
low or not detectable. Negative results in the presence of
MEDI-575would need to be evaluated togetherwithmeasured
MEDI-575 concentration at the same time point to rule out
false-negatives. The sensitivity in assay was determined with a
neutralizing pAb at an LOD of 2440.6 ng/mL back calculated to
undiluted serum sample. Selection of a high-affinity control
NAb may have improved the observed sensitivity of the assay,
but would likely not reflect the true sensitivity in clinical
samples. This is especially true with early or transient NAbs
that have not undergone affinity maturation. The observed
sensitivity is to a large degree a function of the affinity of the
positive control antibody, and has only a loose correlation with
neutralizing ADA encountered in clinical samples.
The approach described here can be useful to eliminate
matrix interference from known components. The addition of
inhibitor to the sample, as shown here, has the advantage of
preserving the potentially complex mixture of anti-drug
61M. Schwickart et al. / Journal of Immunological Methods 403 (2014) 52–61antibodies, leading to an unbiased assay. A readout that is
influenced by many and often unknown factors (e.g. typically
for late readouts like proliferation), has a higher likelihood of
inferior assay window and matrix interference. When the
target-specific signal contributes only to a fraction of the
overall assay signal, the assay window is expected to be
small. Effects from other factors, such as the samples, cells,
and other ADA-independent factors, are likely to cause either
assay variability and/or excessive matrix interference. On the
contrary, if the readout is exclusively specific to the target/
drug, assay variability and matrix effects should be either
minimal or readily controllable as demonstrated in this study.
At the stage when NAb assays are required, extensive
knowledge of the mechanism of action and associated
cellular signaling typically exists and matrix interference is
expected to be readily identified by hypothesis-driven
approaches.
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